Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, R. Gervais et al. · The Lancet Oncology · 2012

Cited by 5,483 works. doi:10.1016/s1470-2045(11)70393-x

Authors

References